AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4054203 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine, 20 mg retard
Number of subjects: 8
Study 31728025 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy arm
Number of subjects: 439
Study 31728025 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense treatment arm
Number of subjects: 439
Study 31728025 — intervention group
Group type: EXPERIMENTAL
Intervention: High AR mRNA levels
Number of subjects: 439
Study 29381494 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-use of marijuana and tobacco
Number of subjects: 52
Study 29381494 — intervention group
Group type: COMPARATOR
Intervention: Only use of tobacco
Number of subjects: 52
Study 26883529 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-Based Learning (TBL)
Number of subjects: 115
Study 26883529 — intervention group
Group type: COMPARATOR
Intervention: Teaching as Usual (TAU)
Number of subjects: 115
Study 24878327 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surgical technique with acellular dermal matrix graft (ADMG)
Number of subjects: 15
Study 24878327 — intervention group
Group type: COMPARATOR
Intervention: Control group with acellular dermal matrix graft (ADMG)
Number of subjects: 15
Study 22498230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation
Number of subjects: 554
Study 22498230 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation
Number of subjects: 554
Study 20117675 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visiting (NV) intervention
Number of subjects: 0
Study 18626830 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration before transfer to the catheterisation laboratory (27 patients)
Number of subjects: 59
Study 18626830 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab administration in the catheterisation laboratory just before pPCI (32 patients)
Number of subjects: 59
Study 15886988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gold implants
Number of subjects: 96
Study 15886988 — intervention group
Group type: COMPARATOR
Intervention: Flexible platinum chains
Number of subjects: 96
Study 11933903 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamide peroxide (Opalescence Quick) for 30 minutes/week for three weeks
Number of subjects: 27
Study 11933903 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide power bleach (Opalescence Xtra) for 30 minutes/week for three weeks
Number of subjects: 27
Study 11933903 — intervention group
Group type: COMPARATOR
Intervention: Control group: stored in distilled water at 37 degrees C for three weeks
Number of subjects: 27
Study 9806046 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccine (vaccine 3)
Number of subjects: 0
Study 9806046 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 9806046 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S malaria vaccine
Number of subjects: 0
Study 7644924 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (135-225 mg/m2) and Carboplatin (250-400 mg/m2)
Number of subjects: 29
Study 2654758 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine therapy (2 g twice daily for 45 weeks)
Number of subjects: 0
Study 2654758 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 321198 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoridazine (10 mg tablets)
Number of subjects: 30
Study 321198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30497312 — intervention group
Group type: COMPARATOR
Intervention: Traditional acupuncture
Number of subjects: 17
Study 30497312 — intervention group
Group type: COMPARATOR
Intervention: Eye acupuncture
Number of subjects: 17
Study 30497312 — intervention group
Group type: COMPARATOR
Intervention: Wrist–ankle acupuncture
Number of subjects: 17
Study 30497312 — intervention group
Group type: COMPARATOR
Intervention: Superficial acupuncture
Number of subjects: 17
Study 30497312 — intervention group
Group type: COMPARATOR
Intervention: Moxibustion
Number of subjects: 17
Study 30497312 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 17
Study 30497312 — intervention group
Group type: COMPARATOR
Intervention: Ear acupuncture
Number of subjects: 17
Study 30497312 — intervention group
Group type: COMPARATOR
Intervention: Abdominal acupuncture
Number of subjects: 17
Study 29577365 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oleuropein
Number of subjects: 20
Study 29577365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26758035 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (IG)
Number of subjects: 30
Study 26758035 — intervention group
Group type: COMPARATOR
Intervention: Standard care (CG)
Number of subjects: 30
Study 24967345 — intervention group
Group type: EXPERIMENTAL
Intervention: NeReBot robotic therapy
Number of subjects: 0
Study 24967345 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation therapy
Number of subjects: 0
Study 22397784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (10 mg nightly) with standard treatment of BPH
Number of subjects: 132
Study 22397784 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment of BPH (placebo group)
Number of subjects: 132
Study 20849433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic mechanical instrumentation (UMI) with home-care use of amine fluoride/stannous fluoride (AmF/SnF(2)) mouthrinse and toothpaste
Number of subjects: 38
Study 18063874 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AmB) prophylaxis
Number of subjects: 99
Study 18063874 — intervention group
Group type: COMPARATOR
Intervention: Control (no antifungal prophylaxis)
Number of subjects: 99
Study 15240596 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing regimen (ID) starting at 0.2 mg/d, increased by 0.2 mg/d increments to a maximum of 0.8 mg/d
Number of subjects: 387
Study 15240596 — intervention group
Group type: COMPARATOR
Intervention: Fixed body weight-based dosing regimen (FD) with sequential doses of 4, 8, and 12 microg/kg.d GH
Number of subjects: 387
Study 11268982 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal pancreatectomy plus end-to-side pancreaticojejunostomy (group A)
Number of subjects: 18
Study 11268982 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticoduodenectomy (group B)
Number of subjects: 18
Study 9564065 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of dermoid cysts with an endobag
Number of subjects: 55
Study 9564065 — intervention group
Group type: COMPARATOR
Intervention: Removal of dermoid cysts without an endobag
Number of subjects: 55
Study 9564065 — intervention group
Group type: EXPERIMENTAL
Intervention: Infertile women (20 total)
Number of subjects: 55
Study 9564065 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 55
Study 7987360 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-tocopherol supplementation
Number of subjects: 30
Study 7987360 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 2657202 — intervention group
Group type: EXPERIMENTAL
Intervention: Kelman‐Multiflex lenses
Number of subjects: 92
Study 2657202 — intervention group
Group type: EXPERIMENTAL
Intervention: Dubroff lenses
Number of subjects: 92
Study 8317646 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lignocaine gel with absorption promoter
Number of subjects: 34
Study 8317646 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 34
Study 357073 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Number of subjects: 600
Study 357073 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Number of subjects: 600
Study 357073 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 consecutive topical applications with APF gel (1.2% F, pH 3.2)
Number of subjects: 600
Study 357073 — intervention group
Group type: COMPARATOR
Intervention: Untreated control groups
Number of subjects: 600
Study 31849093 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Caloric Fatty Diet (HCFD) - 405 kcal/day, 100% fat
Number of subjects: 201
Study 31849093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 31849093 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFD
Number of subjects: 201
Study 31849093 — intervention group
Group type: EXPERIMENTAL
Intervention: HCFD (post hoc analysis)
Number of subjects: 201
Study 30668660 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal miniscrews
Number of subjects: 80
Study 30668660 — intervention group
Group type: COMPARATOR
Intervention: Molar blocks
Number of subjects: 80
Study 28122851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 12
Study 28122851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodiafiltration (HDF)
Number of subjects: 12
Study 28122851 — intervention group
Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 12
Study 27541067 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupressure therapy applied on acupoints (Jagung, Sinmun, Gyogam, Naebunbi) for 3 days during periods of extreme primary dysmenorrhea.
Number of subjects: 91
Study 27541067 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group with skin paper tape without acupressure needle applied on the same acupoints.
Number of subjects: 91
Study 24656425 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether (80 mg once per day during the second week and fourth week)
Number of subjects: 100
Study 24656425 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical looking capsules)
Number of subjects: 100
Study 23272206 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminders
Number of subjects: 0
Study 23272206 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminders under study conditions
Number of subjects: 0
Study 23272206 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminders implemented by the Ministry of Health
Number of subjects: 0
Study 23272206 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminders scaled up nationally
Number of subjects: 0
Study 23272206 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminders with a 5% effect size
Number of subjects: 0
Study 19440077 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (36, 54, 72, 90, or 108 mg/d)
Number of subjects: 226
Study 19440077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 19440077 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 226
Study 17264729 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg neosaxitoxin
Number of subjects: 10
Study 17264729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15161378 — intervention group
Group type: EXPERIMENTAL
Intervention: Visually influenced (McGurk) responses when the auditory signal was a nonword and formed a word (Experiment 1)
Number of subjects: 0
Study 15161378 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow responses (Experiment 2)
Number of subjects: 0
Study 15161378 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimuli matched on physical properties (Experiment 3)
Number of subjects: 0
Study 11642642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spa-exercise therapy (3 weeks duration) including group physical exercises, walking, correction therapy, hydrotherapy, sports, and sauna visits.
Number of subjects: 120
Study 11642642 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual drug treatment and weekly group physical therapy).
Number of subjects: 120
Study 9697742 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod treatment
Number of subjects: 0
Study 8015082 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 0
Study 8015082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 0
Study 8015082 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 8015082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2492232 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide acetate (LA) 3.75 mg IM every 4 weeks for 24 weeks (Group A)
Number of subjects: 38
Study 2492232 — intervention group
Group type: COMPARATOR
Intervention: IM placebo with the same injection schedule (Group B)
Number of subjects: 38
Study 4338548 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous alpha and beta receptor blockade
Number of subjects: 5
Study 30278943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging (FI) using indocyanine green
Number of subjects: 110
Study 30278943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluorescence imaging)
Number of subjects: 110
Study 30278943 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging (FI)
Number of subjects: 110
Study 27181910 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 5 to 40 mg once daily for 24 weeks
Number of subjects: 447
Study 27181910 — intervention group
Group type: EXPERIMENTAL
Intervention: Teneligliptin 20 mg once daily during 28-week open label extension
Number of subjects: 447
Study 27181910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 447
Study 24838155 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day)
Number of subjects: 178
Study 24838155 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin (5 mg once daily)
Number of subjects: 178
Study 24838155 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 178
Study 24838155 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 178
Study 22584293 — intervention group
Group type: EXPERIMENTAL
Intervention: Plastic ring drape
Number of subjects: 199
Study 22584293 — intervention group
Group type: COMPARATOR
Intervention: Standard cloth towels (control)
Number of subjects: 199
Study 20144258 — intervention group
Group type: EXPERIMENTAL
Intervention: Rooibos tea (400 ml)
Number of subjects: 17
Study 20144258 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea (400 ml)
Number of subjects: 17
Study 18396251 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (unilateral manual stimulation of acupuncture points LU7 and KD6)
Number of subjects: 60
Study 18396251 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 60
Study 16288142 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital‐relationship enhancement program (MREP) based on Gottman's 'sound marital house' theory
Number of subjects: 71
Study 16288142 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 71
Study 12705519 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n=7)
Number of subjects: 13
Study 12705519 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=6)
Number of subjects: 13
Study 10806051 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg)
Number of subjects: 16
Study 10806051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8841291 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive keratotomy using the Casebeer system
Number of subjects: 324
Study 1732429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of high-dose recombinant interleukin-2 (rIL-2) three times daily
Number of subjects: 94
Study 1732429 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of high-dose recombinant interleukin-2 (rIL-2) 24-hour infusion
Number of subjects: 94
Study 6396239 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 45
Study 6396239 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide-amiloride combination
Number of subjects: 45
Study 30964238 — intervention group
Group type: EXPERIMENTAL
Intervention: Guava toner with 6% guava extract
Number of subjects: 21
Study 30964238 — intervention group
Group type: COMPARATOR
Intervention: Base toner (control)
Number of subjects: 21
Study 29024599 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training with probiotics (CTP)
Number of subjects: 48
Study 29024599 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training (CT)
Number of subjects: 48
Study 29024599 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (P)
Number of subjects: 48
Study 29024599 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit training with placebo (CT)
Number of subjects: 48
Study 29024599 — intervention group
Group type: COMPARATOR
Intervention: Sedentary placebo control
Number of subjects: 48
Study 27433807 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation of left DLPFC
Number of subjects: 42
Study 27433807 — intervention group
Group type: COMPARATOR
Intervention: Cathodal stimulation of left DLPFC
Number of subjects: 42
Study 27433807 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation of left DLPFC
Number of subjects: 42
Study 24910546 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 231
Study 24910546 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 231
Study 22864336 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (ERT) plus vaginal brachytherapy (VBT)
Number of subjects: 527
Study 22864336 — intervention group
Group type: COMPARATOR
Intervention: Vaginal irradiation alone (VBT)
Number of subjects: 527
Study 20557927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-monitored ART care
Number of subjects: 812
Study 20557927 — intervention group
Group type: COMPARATOR
Intervention: Doctor-monitored ART care
Number of subjects: 812
Study 18608310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for GAD
Number of subjects: 29
Study 16108073 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portal-systemic shunting (TIPS)
Number of subjects: 109
Study 16108073 — intervention group
Group type: COMPARATOR
Intervention: Repeated large volume paracentesis (LVP)
Number of subjects: 109
Study 12001821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 5 mg
Number of subjects: 16
Study 12001821 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 5 mg
Number of subjects: 16
Study 12001821 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 2.5 mg
Number of subjects: 16
Study 12001821 — intervention group
Group type: COMPARATOR
Intervention: Oxybutynin 7.5 mg
Number of subjects: 16
Study 10726106 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week hypocaloric diet (3.9 MJ (941 kcal))
Number of subjects: 15
Study 7795832 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss alone
Number of subjects: 2382
Study 7795832 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted sodium intake alone
Number of subjects: 2382
Study 7795832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of weight loss and sodium restriction
Number of subjects: 2382
Study 7795832 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2382
Study 1953227 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin cream
Number of subjects: 252
Study 1953227 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 252
Study 6969867 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic cerebellar stimulation
Number of subjects: 8
Study 6969867 — intervention group
Group type: COMPARATOR
Intervention: Placebo (functional or placebo stimulation)
Number of subjects: 8
Study 31498308 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed pulmonary exercise group (PG)
Number of subjects: 0
Study 31498308 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control group (CG)
Number of subjects: 0
Study 27815861 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity physical activity
Number of subjects: 52
Study 27815861 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary activity
Number of subjects: 52
Study 26529311 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance plan implemented across clinical centers and central reading units
Number of subjects: 0
Study 24577921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocucure (Test drug) 500mg, two tablets twice daily for 6-8 weeks
Number of subjects: 111
Study 24577921 — intervention group
Group type: COMPARATOR
Intervention: Leutivit (Control drug) 250mg, two tablets twice daily for 6-8 weeks
Number of subjects: 111
Study 24577921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocucure (Test drug)
Number of subjects: 111
Study 21183110 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard corneal collagen crosslinking (CXL)
Number of subjects: 15
Study 21183110 — intervention group
Group type: COMPARATOR
Intervention: Sham control (riboflavin alone)
Number of subjects: 15
Study 20025421 — intervention group
Group type: EXPERIMENTAL
Intervention: Human figure drawings (HFDs)
Number of subjects: 0
Study 20025421 — intervention group
Group type: COMPARATOR
Intervention: Verbal condition
Number of subjects: 0
Study 20025421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HFD and verbal conditions
Number of subjects: 0
Study 17183019 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved stoves (planchas)
Number of subjects: 504
Study 17183019 — intervention group
Group type: COMPARATOR
Intervention: Traditional open fires
Number of subjects: 504
Study 14749712 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 6500
Study 14749712 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6500
Study 12564317 — intervention group
Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph II
Number of subjects: 20
Study 9695216 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (1.5-2.0 mg/kg/day for 6 months)
Number of subjects: 31
Study 9695216 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulses (20 mg/kg/monthly for at least 6 pulses) combined with oral prednisolone (40-60 mg/day for 1.5 months with tapering)
Number of subjects: 31
Study 9695216 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide
Number of subjects: 31